Effects of prescribed antihypertensives and other cardiovascular drugs on mortality in patients with atrial fibrillation and hypertension: A cohort study from Sweden

Hypertension Research

Volumn 37, Issue 6, 2014, Pages 553-559

  Carlsson, Axel C ^a,b   Wändell, Per ^a   Sundquist, Kristina ^c,d   Johansson, Sven Erik ^c   Sundquist, Jan ^c,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

calcium antagonists; diuretics; pharmacotherapy; propensity score statins

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; SOTALOL; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; DRUG CLASSIFICATION; DRUG EFFECT; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MARRIAGE; PRESCRIPTION; PROPENSITY SCORE; SWEDEN; ATRIAL FIBRILLATION; DRUG COMBINATION; MIDDLE AGED; MORTALITY; REGRESSION ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; CARDIOVASCULAR AGENTS; COHORT STUDIES; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SWEDEN; TREATMENT OUTCOME;

EID: 84901986931     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2014.32     Document Type: Article

References (40)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., Jones DW, Materson BJ, Oparil S, Wright JT Jr., Roccella EJ. The Seventh Report of the JointNational Committee on Prevention, Detection, Evaluation, and Treatment of High BloodPressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL. 2007Guidelines for the management of arterial hypertension: the task force for themanagement of arterial hypertension of the European Society of Hypertension (ESH)and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536.
3. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascularevents: results of prospectively-designed overviews of randomised trials.Lancet 2003; 362: 1527-1535.
4. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Woodward M, MacMahon S. Effects of different blood pressure-lowering regimens on majorcardiovascular events in individuals with and without diabetes mellitus: results ofprospectively designed overviews of randomized trials. Arch Intern Med 2005; 165:1410-1419.
5. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S. Effectsof different regimens to lower blood pressure on major cardiovascular events in olderand younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-1123.
6. Knottnerus JA, Tugwell P. Requirements for utilizing health care-based data sources forresearch. J Clin Epidemiol 2011; 64: 1051-1053.
7. Wandell PE. A survey of subjects with present or previous atrial fibrillation in a swedishcommunity. Scand J Prim Health Care 2001; 19: 20-24.
8. Bajpai A, Savelieva I, Camm AJ. Treatment of atrial fibrillation. Br Med Bull 2008; 88:75-94.
9. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, agedistribution, and gender of patients with atrial fibrillation. Analysis and implications.Arch Intern Med 1995; 155: 469-473.
10. Wandell P, Carlsson AC, Sundquist K, Johansson SE, Sundquist J. Effect ofcardiovascular drug classes on all-cause mortality among atrial fibrillation patientstreated in primary care in Sweden: a cohort study. Eur J Clin Pharmacol 2013; 69:279-287.
11. Carlsson AC, Wandell P, Sundquist K, Johansson SE, Sundquist J. Differences andtime trends in drug treatment of atrial fibrillation in men and women and doctors'adherence to warfarin therapy recommendations: a Swedish study of prescribed drugsin primary care in 2002 and 2007. Eur J Clin Pharmacol 2013; 69: 245-253.
12. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K, Zamboulis C. Prevalence of primary hyperaldosteronismin resistant hypertension: a retrospective observational study. Lancet 2008; 371:1921-1926.
13. Furberg CD. Treatment of hypertension: failing report card. Am J Hypertens 2009; 22:1-2.
14. Sundquist K, Li X. Coronary heart disease risks in first-and second-generationimmigrants in sweden: a follow-up study. J Intern Med 2006; 259: 418-427.
15. Wandell PE, Carlsson AC, Sundquist K, Johansson SE, Sundquist J. Total mortalityamong levothyroxine-treated women with atrial fibrillation in Swedish primary healthcare. Int J Cardiol 2011; 152: 147-148.
16. Seiler J, Stevenson WG. Atrial fibrillation in congestive heart failure. Cardiol Rev 2010;18: 38-50.
17. Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M. Stroke prophylaxis inatrial fibrillation: Who gets it and who does not? Report from the Stockholm cohortstudyon atrial fibrillation (SCAF-study). Eur Heart J 2006; 27: 1954-1964.
18. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr., Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. ACC/AHA/ESC 2006 guidelines for themanagement of patients with atrial fibrillation: full text: a report of the AmericanCollege of Cardiology/American Heart Association Task Force on practice guidelinesand the European Society Of Cardiology Committee for practice guidelines (writingcommittee to revise the 2001 guidelines for the management of patients with atrialfibrillation) developed in collaboration with the european heart rhythm association andthe heart rhythm society. Europace 2006; 8: 651-745.
19. Dahabreh IJ, Sheldrick RC, Paulus JK, Chung M, Varvarigou V, Jafri H, Rassen JA, Trikalinos TA, Kitsios GD. Do observational studies using propensity score methodsagree with randomized trials? A systematic comparison of studies on acute coronarysyndromes. Eur Heart J 2012; 33: 1893-1901.
20. Carlsson AC, Wandell PE, Journath G, de Faire U, Hellenius ML. Factors associatedwith uncontrolled hypertension and cardiovascular risk in hypertensive 60-year-oldmen and women-a population-based study. Hypertens Res 2009; 32: 780-785.
21. Journath G, Hellenius ML, Carlsson AC, Wandell PE, Nilsson PM. Physicians' gender isassociated with risk factor control in patients on antihypertensive and lipid loweringtreatment. Blood Press 2010; 19: 240-248.
22. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, Moskowitz MA.Inadequate management of blood pressure in a hypertensive population. New Engl JMed 1998; 339: 1957-1963.
23. Grandi AM, Maresca AM, Sessa A, Stella R, Ponti D, Barlocco E, Banfi F, Venco A.Longitudinal study on hypertension control in primary care: The Insubria study. Am JHypertens 2006; 19: 140-145.
24. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, andcontrol of hypertension among united states adults 1999-2004. Hypertension 2007;49: 69-75.
25. Volpe M, Tocci G, Trimarco B, Rosei EA, Borghi C, Ambrosioni E, Menotti A, ZanchettiA, Mancia G. Blood pressure control in italy: results of recent surveys on hypertension.J Hypertens 2007; 25: 1491-1498.
26. Farsang C. Indications for and utilization of angiotensin receptor ii blockers in patientsat high cardiovascular risk. Vasc Health Risk Manag 2011; 7: 605-622.
27. Hudson M, Rahme E, Behlouli H, Sheppard R, Pilote L. Sex differences in theeffectiveness of angiotensin receptor blockers and angiotensin converting enzymeinhibitors in patients with congestive heart failure-a population study. Eur J Heart Fail2007; 9: 602-609.
28. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Majoroutcomes in high-risk hypertensive patients randomized to angiotensin-convertingenzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive andLipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
29. Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R.Role of diuretics in the prevention of heart failure: the antihypertensive andlipid-lowering treatment to prevent heart attack trial. Circulation 2006; 113:2201-2210.
30. de Koning JS, Klazinga NS, Koudstaal PJ, Prins A, Borsboom GJ, Mackenbach JP. Therole of 'confounding by indication' in assessing the effect of quality of care on diseaseoutcomes in general practice: results of a case-control study. BMC Health Serv Res2005; 5: 10.
31. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drugtreatment for hypertension. BMJ 1997; 315: 1151-1154.
32. Carlsson AC, Wandell P, Sundquist K, Johansson SE, Sundquist J. Differences andtime trends in drug treatment of atrial fibrillation in men and women and doctors'adherence to warfarin therapy recommendations: a Swedish study of prescribed drugsin primary care in 2002 and 2007. Eur J Clin Pharmacol 2012; 69: 245-253.
33. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90, 056 participants in 14 randomised trials ofstatins. Lancet 2005; 366: 1267-1278.
34. Goonasekara CL, Balse E, Hatem S, Steele DF, Fedida D. Cholesterol and cardiacarrhythmias. Expert Rev Cardiovasc Ther 2010; 8: 965-979.
35. Bachmann JM, Majmudar M, Tompkins C, Blumenthal RS, Marine JE. Lipid-alteringtherapy and atrial fibrillation. Cardiol Rev 2008; 16: 197-204.
36. Henriksson KM, Farahmand B, Johansson S, Asberg S, Terent A, Edvardsson N.Survival after stroke-the impact of chads2 score and atrial fibrillation. Int J Cardiol2010; 141: 18-23.
37. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for strokedespite anticoagulation: a comparison of contemporary stroke risk stratificationschemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41: 2731-2738.
38. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratificationfor predicting stroke and thromboembolism in atrial fibrillation using a novel riskfactor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137:263-272.
39. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versuspropensity score when the number of events is low and there are multiple confounders.Am J Epidemiol 2003; 158: 280-287.
40. Sundquist K, Chaikiat A, Leon VR, Johansson SE, Sundquist J. Country of birth, socioeconomic factors, and risk factor control in patients with type 2 diabetes: aSwedish study from 25 primary health-care centres. Diabetes Metab Res Rev 2011;27: 244-254.